EP1363890A4 - Melanocortin-4 receptor binding compounds and methods of use thereof - Google Patents
Melanocortin-4 receptor binding compounds and methods of use thereofInfo
- Publication number
- EP1363890A4 EP1363890A4 EP02718920A EP02718920A EP1363890A4 EP 1363890 A4 EP1363890 A4 EP 1363890A4 EP 02718920 A EP02718920 A EP 02718920A EP 02718920 A EP02718920 A EP 02718920A EP 1363890 A4 EP1363890 A4 EP 1363890A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- melanocortin
- binding compounds
- receptor binding
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US778468 | 2001-02-07 | ||
US09/778,468 US6699873B1 (en) | 1999-08-04 | 2001-02-07 | Melanocortin-4 receptor binding compounds and methods of use thereof |
PCT/US2002/003566 WO2002062766A2 (en) | 2001-02-07 | 2002-02-07 | Melanocortin-4 receptor binding compounds and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1363890A2 EP1363890A2 (en) | 2003-11-26 |
EP1363890A4 true EP1363890A4 (en) | 2009-06-10 |
Family
ID=25113443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02718920A Withdrawn EP1363890A4 (en) | 2001-02-07 | 2002-02-07 | Melanocortin-4 receptor binding compounds and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1363890A4 (en) |
WO (1) | WO2002062766A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1404324B2 (en) * | 2001-06-11 | 2011-04-06 | XenoPort, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
UA81749C2 (en) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Derivated of phenylpiperazine as serotonin reuptake inhibitorS |
US7858631B2 (en) | 2002-05-23 | 2010-12-28 | Novartis Vaccines And Diagnostics, Inc. | Substituted pyrido [2,3-d] pyrimidinone compounds |
AU2003242092A1 (en) * | 2002-06-11 | 2003-12-22 | Sankyo Company, Limited | Process for producing cyclic thioether and synthetic intermediate thereof |
US7396930B2 (en) | 2002-06-11 | 2008-07-08 | Sankyo Company, Limited | Process for producing cyclic thioether and synthetic intermediate thereof |
KR100863667B1 (en) * | 2002-09-11 | 2008-10-15 | 가부시끼가이샤 구레하 | Amine Compound and Use Thereof |
ES2412273T3 (en) * | 2002-11-21 | 2013-07-10 | Novartis Ag | 2-Morpholin-4-pyrimidine inhibitors such as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer. |
ATE440827T1 (en) | 2002-12-04 | 2009-09-15 | Ore Pharmaceuticals Inc | MELANOCORTIN RECEPTOR MODULATORS |
JP4667366B2 (en) | 2003-04-04 | 2011-04-13 | ハー・ルンドベック・アクチエゼルスカベット | 4- (2-Phenylsulfanyl-phenyl) -piperidine derivatives as serotonin reuptake inhibitors |
EP1651229A1 (en) * | 2003-05-23 | 2006-05-03 | Chiron Corporation | Guanidino-substituted quinazolinone compounds as mc4-r agonists |
DK1701940T3 (en) | 2003-12-23 | 2008-09-08 | Lundbeck & Co As H | 2- (1H-indolylsulfanyl) benzylamine derivatives as SSRIs |
US7932281B2 (en) | 2004-03-10 | 2011-04-26 | Kureha Corporation | Amine-based compound and use thereof |
AR052308A1 (en) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -ARILAMINE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND |
US8795725B2 (en) | 2004-11-04 | 2014-08-05 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
WO2006081289A2 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
EP1854787B1 (en) * | 2005-03-03 | 2010-09-01 | Santen Pharmaceutical Co., Ltd. | Novel cyclic compound having quinolylalkylthio group |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
AR054393A1 (en) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | DERIVATIVES OF BENZO (B) FURANO AND BENZO (B) THIOPHEN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE REINFORCEMENT OF AMINA BOSS NEUTRANTS. |
ES2476027T3 (en) | 2005-10-25 | 2014-07-11 | Shionogi & Co., Ltd. | Aminodihydrotriazine derivatives |
EP1948639A2 (en) * | 2005-11-11 | 2008-07-30 | F. Hoffmann-la Roche AG | Novel carbocyclic fused cyclic amines |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
JP5383483B2 (en) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | Pharmaceutical composition for the treatment of Alzheimer's disease |
JP5383484B2 (en) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | Aminodihydrothiazine derivatives substituted with cyclic groups |
EP2072050A1 (en) | 2007-12-21 | 2009-06-24 | Santhera Pharmaceuticals (Schweiz) AG | Compounds with anti-emetic effect |
KR101324426B1 (en) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN102186841A (en) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity |
EP2362731B1 (en) | 2008-10-31 | 2016-04-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8759539B2 (en) | 2008-11-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2010065801A1 (en) * | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperazine melanocortin receptor-specific compounds |
MX2011011516A (en) | 2009-04-30 | 2011-11-18 | Astex Therapeutics Ltd | Imidazole derivatives and their use as modulators of cyclin dependent kinases. |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
MX2012006491A (en) | 2009-12-11 | 2012-07-03 | Shionogi & Co | Oxazine derivative. |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | Fused aminodihydropyrimidine derivative |
AU2011321427A1 (en) | 2010-10-29 | 2013-05-02 | Shionogi & Co., Ltd. | Naphthyridine derivative |
WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
KR101668514B1 (en) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
EA025183B1 (en) | 2011-09-27 | 2016-11-30 | Новартис Аг | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
UY34632A (en) | 2012-02-24 | 2013-05-31 | Novartis Ag | OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME |
KR20150036245A (en) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | Antidiabetic tricyclic compounds |
JP2016501827A (en) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Dihydrooxazine or oxazepine derivative having BACE1 inhibitory action |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
US10059671B2 (en) | 2013-02-04 | 2018-08-28 | Prexton Therapeutics Sa | Positive allosteric modulators of mGluR3 |
CN104994848A (en) | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
MX355945B (en) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh. |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JPWO2016056606A1 (en) * | 2014-10-07 | 2017-07-20 | 国立大学法人京都大学 | Benzisothiazolopyrimidine derivatives or salts thereof, viral infection inhibitors and pharmaceuticals |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
TWI794742B (en) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | Antiviral compounds |
CN117120444A (en) | 2021-04-16 | 2023-11-24 | 吉利德科学公司 | Method for preparing carbanucleoside using amide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2219841A1 (en) * | 1972-04-22 | 1973-10-25 | Basf Ag | PROCESS FOR THE PREPARATION OF 2- (OALKYLTHIOPHENYL) -1,3-DIAZACYCLOALKENHYDROHALOGENIDES |
US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
CA2334551A1 (en) * | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
AU6621600A (en) * | 1999-08-04 | 2001-03-05 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
-
2002
- 2002-02-07 EP EP02718920A patent/EP1363890A4/en not_active Withdrawn
- 2002-02-07 WO PCT/US2002/003566 patent/WO2002062766A2/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
WO2002062766A2 (en) | 2002-08-15 |
WO2002062766A3 (en) | 2002-10-03 |
EP1363890A2 (en) | 2003-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002062766A3 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
WO2001010842A3 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
WO2002002525A3 (en) | N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity | |
WO2000046203A3 (en) | G-protein coupled heptahelical receptor binding compounds and methods of use thereof | |
WO2004050610A3 (en) | Modulators of melanocortin receptor | |
MY129613A (en) | Cannabinoid receptor binding compounds | |
WO2005000820A3 (en) | 4-cyanopyrazole-3-carboxamide derivatives preparation and application thereof as cb1 cannabinoid antagonists | |
WO2003024401A3 (en) | Piperizinones as modulators of chemokine receptor activity | |
IL142768A0 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
WO2003087094A3 (en) | Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors | |
AU2001270070A1 (en) | Nitrosated and nitrosylated taxanes, compositions and methods of use | |
WO2002032874A3 (en) | Substituted heterocyclic compounds for treating multidrug resistance | |
WO2003093269A3 (en) | Substituted pyrazolo-pyrimidine-4-ones | |
AU3126600A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
WO2003024928A3 (en) | Novel aminoazetidine, -pyrrolidine and -piperidine derivatives | |
AU3713600A (en) | Nitrosated and nitrosylated prostaglandins, compositions and metods of use | |
WO2001017973A3 (en) | Novel herbicides | |
WO2003030937A1 (en) | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | |
WO2006066950A3 (en) | Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents | |
WO2001090071A3 (en) | Substituted iminoazines used as herbicides | |
WO2001028987A8 (en) | Benzylcycloalkyl amines as modulators of chemokine receptor activity | |
WO2000044763A3 (en) | Compositions for treating inflammatory response | |
WO2002070469A3 (en) | Selective pde3b inhibitors and use of the same in therapy | |
WO2001098270A3 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
WO2002010152A3 (en) | Novel indole derivatives and their use as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030820 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RTI1 | Title (correction) |
Free format text: MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ORE PHARMACEUTICALS INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090513 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/00 20060101ALI20090507BHEP Ipc: A61K 31/505 20060101ALI20090507BHEP Ipc: A61K 31/4164 20060101ALI20090507BHEP Ipc: A61K 31/4184 20060101ALI20090507BHEP Ipc: C07D 233/20 20060101ALI20090507BHEP Ipc: C07D 239/06 20060101ALI20090507BHEP Ipc: C07D 235/06 20060101AFI20020819BHEP |
|
17Q | First examination report despatched |
Effective date: 20090911 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110521 |